TMO — Thermo Fisher Scientific Inc.

Summary of Thermo Fisher Scientific Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $11.99 billion, up 10% year-over-year.
• Adjusted Operating Income: $2.73 billion, a 15% increase.
• Adjusted Operating Margin: 22.8%, up 90 basis points.
• Adjusted EPS: $6.03, reflecting a 13% growth.
• Organic Revenue Growth: 5% in Q2, with notable contributions from acquisitions and favorable foreign exchange.
• Free Cash Flow: $2.5 billion year-to-date, with $3.3 billion in cash flow from operations.
• Debt: Total debt of $42.5 billion, with a leverage ratio of 3.6x gross debt to adjusted EBITDA.

2. Strategic Updates and Business Highlights

• Growth Strategy: Focused on high-impact innovation, trusted partner status with customers, and a strong commercial engine.
• Innovations: Launched several new technologies, including next-generation mass spectrometers and AI-driven capabilities, enhancing scientific research.
• Acquisitions: Successful integration of Clario, enhancing clinical insights for pharma and biotech customers. The filtration and separation business also performed well.
• Divestiture: Announced the divestiture of the microbiology business, expected to close in Q3, with proceeds used for share repurchases.
• CSR Initiatives: Continued progress on sustainability goals, including Net Zero roadmap and STEM education programs.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised to $47.4 billion to $48.1 billion, representing 6% to 8% growth over 2025.
• Adjusted EPS Guidance: Increased to $24.93 to $25.33, indicating 9% to 11% growth.
• Organic Revenue Growth: Expected to be around 4% for the year, with Q3 and Q4 anticipated to show similar growth rates.
• Acquisition Contributions: Expected to contribute $1.6 billion in revenue and $0.32 to adjusted EPS for the year.

4. Bad News, Challenges, or Points of Concern

• Market Stability: Academic and government markets remain in a stabilization phase, with no significant changes in outlook despite Q2 growth.
• China Performance: Low single-digit growth in China, with academic and government sectors still muted.
• Divestiture Impact: The microbiology business divestiture will reduce 2026 revenue by approximately $200 million and adjusted EPS by $0.05.
• Competitive Pressures: Ongoing challenges from macroeconomic factors, including tariffs and reshoring dynamics affecting large pharma spending.

5. Notable Q&A Insights

• Customer Activity: Increased customer activity noted across end markets, particularly in pharma and biotech, with expectations for continued growth.
• Pharma Services: Strong performance in clinical research, with a positive outlook for the second half of the year driven by increased authorizations.
• Analytical Instruments: Notable growth attributed to product launches and strong global demand, particularly in academic settings.
• Bioproduction: Continued strength in bioproduction business, with new technologies gaining traction and contributing to growth.
• Market Dynamics: Executives expressed optimism about the recovery in biotech and academic sectors, although caution was advised regarding the sustainability of growth trends.

Overall, Thermo Fisher Scientific reported a strong quarter with robust financial performance and strategic advancements, while also acknowledging challenges in certain markets and the impact of external economic factors.